Interacción de Butalbital, ácido acetilsalicílico, cafeína y codeína con Oxibato de sodio
Butalbital, ácido acetilsalicílico, cafeína y codeína con Oxibato de sodio: ambas etiquetas de prescripción advierten sobre esta combinación con el lenguaje más contundente, como una contraindicación, una advertencia en recuadro o la indicación de evitarla.
No combinar sin la orientación de un prescriptor. El lenguaje de la etiqueta que aparece a continuación es el más contundente que usa la FDA.
Qué dicen las etiquetas de la FDA
De la etiqueta de Oxibato de sodio (Xyrem) · vigente desde 2025-07-01
• Central Nervous System Depression Xyrem (sodium oxybate) is a CNS depressant.
Many patients who received Xyrem during clinical trials in narcolepsy were receiving central nervous system stimulants [see Clinical Trials ( 14 )].
Abuse or misuse of illicit GHB, either alone or in combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death [see Warnings and Precautions ( 5.2 )].
Central Nervous System Depression • Xyrem is a CNS depressant, and respiratory depression can occur with Xyrem use ( 5.1 , 5.4 )
Abuse of illicit GHB, either alone or in combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death.
De la etiqueta de Butalbital, ácido acetilsalicílico, cafeína y codeína (BUTALBITAL, ASPIRIN, CAFFEINE and CODEINE PHOSPHATE) · vigente desde 2026-01-15
Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death.
Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death.
Reserve concomitant prescribing of BUTALBITAL, ASPIRIN, CAFFEINE and CODEINE PHOSPHATE and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate. [see Warnings and Precautions ( 5.3 , 5.9 ), Drug Interactions ( 7 )].
Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Profound sedation, respiratory depression, coma, and death may result from the concomitant use of BUTALBITAL, ASPIRIN, CAFFEINE and CODEINE PHOSPHATE with benzodiazepines and/or other CNS depressants, including alcohol (e.g., non-benzodiazepine sedatives/hypnotics, anxiolytics, tranquilizers,…
Screen patients for risk of substance use disorders, including opioid abuse and misuse, and warn them of the risk for overdose and death associated with the use of additional CNS depressants including alcohol and illicit drugs [see Drug Interactions ( 7 ) and Patient Counseling Information ( 17 ) ].
¿Toma algo más además de estos dos? Las interacciones se acumulan. Compruebe toda su lista de una vez; se queda en su navegador.
Abrir en el verificadorNo es un consejo médico. Interaction Checker cita el texto de las etiquetas de la FDA y las hojas informativas de los NIH. Que una interacción sea importante en su caso depende de las dosis, el momento de las tomas, la función renal y hepática y otras afecciones. Confírmelo con un farmacéutico o un prescriptor.